{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T05:30:07Z","timestamp":1773379807929,"version":"3.50.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2018,5,29]],"date-time":"2018-05-29T00:00:00Z","timestamp":1527552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Vifor (International) Inc., Switzerland"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,7,1]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n Treatment of hyperphosphataemia is the primary goal of chronic kidney disease\u2013mineral and bone disorder (CKD-MBD) management. This post hoc analysis of a randomized, Phase 3 study evaluated the effects of 1-year treatment with the phosphate binders sucroferric oxyhydroxide or sevelamer carbonate (\u2018sevelamer\u2019) on CKD-MBD indices among dialysis patients with hyperphosphataemia.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n After a 2- to 4-week washout from previous phosphate binders, 1059 patients were randomized 2:1 to sucroferric oxyhydroxide 1.0\u20133.0\u2009g\/day (n\u2009=\u2009710) or sevelamer 2.4\u201314.4\u2009g\/day (n\u2009=\u2009349) for up to 24\u2009weeks. Eligible patients enrolled in a 28-week extension. This post hoc analysis was performed for patients who completed \u22651 year of continuous treatment (n\u2009=\u2009549). As the treatment groups showed similar CKD-MBD outcomes, the data were pooled for this analysis.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Phosphate-binder therapy was associated with significant and sustained 30% reductions in serum phosphorus (P\u2009<\u20090.001). Median intact fibroblast growth factor-23 (FGF-23) also significantly decreased (P\u2009<\u20090.001) by 64% over 1\u2009year. Intact parathyroid hormone decreased significantly after 24\u2009weeks (P\u2009<\u20090.001), but levels returned to near baseline values by Week 52; minimal changes in serum calcium were observed. Of the bone resorption markers evaluated, tartrate-resistant acid phosphatase 5b (TRAP5b) decreased significantly (P\u2009<\u20090.001), whereas CTx increased transiently but returned to baseline levels by Week 52. The bone formation markers bone-specific alkaline phosphatase and osteocalcin both increased over 1\u2009year of treatment.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Overall, 1 year of sucroferric oxyhydroxide or sevelamer treatment significantly reduced serum FGF-23, which has been associated with clinical benefit in patients with CKD. The trend towards increased bone formation marker levels indicates a beneficial effect on bone metabolism.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/ndt\/gfy127","type":"journal-article","created":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T23:33:21Z","timestamp":1525390401000},"page":"1163-1170","source":"Crossref","is-referenced-by-count":34,"title":["Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease\u2013mineral bone disorder parameters in dialysis patients"],"prefix":"10.1093","volume":"34","author":[{"given":"Markus","family":"Ketteler","sequence":"first","affiliation":[{"name":"Klinikum Coburg and KfH-Dialysis Center, Coburg, Germany"},{"name":"School of Medicine, University of Split, Split, Croatia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart M","family":"Sprague","sequence":"additional","affiliation":[{"name":"NorthShore University Health System, University of Chicago, Pritzker School of Medicine, Evanston, IL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian C","family":"Covic","sequence":"additional","affiliation":[{"name":"Gr.T. Popa University of Medicine and Pharmacy, Iasi, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anjay","family":"Rastogi","sequence":"additional","affiliation":[{"name":"David Geffen School of Medicine, University of California, Los Angeles, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Spinowitz","sequence":"additional","affiliation":[{"name":"New York Presbyterian Queens, Flushing, NY, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viatcheslav","family":"Rakov","sequence":"additional","affiliation":[{"name":"Vifor Pharma, Glattbrugg, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Walpen","sequence":"additional","affiliation":[{"name":"Vifor Pharma, Glattbrugg, Zurich, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00fcrgen","family":"Floege","sequence":"additional","affiliation":[{"name":"RWTH University Hospital Aachen, Aachen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,5,29]]},"reference":[{"key":"2019070203524493200_gfy127-B1","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"2019070203524493200_gfy127-B2","first-page":"303","article-title":"Pathophysiology of the chronic kidney disease-mineral bone disorder","volume":"24","author":"Hruska","year":"2015","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2019070203524493200_gfy127-B3","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMoa0706130","article-title":"Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis","volume":"359","author":"Guti\u00e9rrez","year":"2008","journal-title":"N Engl J Med"},{"key":"2019070203524493200_gfy127-B4","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"2019070203524493200_gfy127-B5","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1053\/j.ajkd.2008.03.020","article-title":"Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)","volume":"52","author":"Tentori","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"2019070203524493200_gfy127-B6","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1001\/jama.2011.826","article-title":"Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease","volume":"305","author":"Isakova","year":"2011","journal-title":"JAMA"},{"key":"2019070203524493200_gfy127-B7","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1172\/JCI46122","article-title":"FGF23 induces left ventricular hypertrophy","volume":"121","author":"Faul","year":"2011","journal-title":"J Clin Invest"},{"key":"2019070203524493200_gfy127-B8","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1681\/ASN.2014101009","article-title":"Low vitamin D and high fibroblast growth factor 23 serum levels associate with infectious and cardiac deaths in the HEMO study","volume":"27","author":"Chonchol","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2019070203524493200_gfy127-B9","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1016\/j.bone.2012.02.634","article-title":"Intact fibroblast growth factor 23 levels predict incident cardiovascular event before but not after the start of dialysis","volume":"50","author":"Nakano","year":"2012","journal-title":"Bone"},{"key":"2019070203524493200_gfy127-B10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.kint.2017.04.006","article-title":"Executive summary of the 2017 KDIGO Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update: what\u2019s changed and why it matters","volume":"92","author":"Ketteler","year":"2017","journal-title":"Kidney Int"},{"key":"2019070203524493200_gfy127-B11","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nrneph.2011.112","article-title":"Pharmacology, efficacy and safety of oral phosphate binders","volume":"7","author":"Hutchison","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"2019070203524493200_gfy127-B12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5414\/CN107764","article-title":"The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients","volume":"80","author":"Soriano","year":"2013","journal-title":"Clin Nephrol"},{"key":"2019070203524493200_gfy127-B13","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1744-9987.2005.00293.x","article-title":"Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients","volume":"9","author":"Koiwa","year":"2005","journal-title":"Therapher Dial"},{"key":"2019070203524493200_gfy127-B14","author":"Block"},{"key":"2019070203524493200_gfy127-B15","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1038\/ki.2014.58","article-title":"A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients","volume":"86","author":"Floege","year":"2014","journal-title":"Kidney Int"},{"key":"2019070203524493200_gfy127-B16","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1093\/ndt\/gfv006","article-title":"Long-term effects of iron-based phosphate binder, sucroferric oxyhydroxide, in dialysis patients","volume":"30","author":"Floege","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2019070203524493200_gfy127-B17","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/CIRCULATIONAHA.114.013876","article-title":"Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial","volume":"132","author":"Moe","year":"2015","journal-title":"Circulation"},{"key":"2019070203524493200_gfy127-B18","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1124\/jpet.113.204792","article-title":"PA21, a new iron-based noncalcium phosphate binder, prevents vascular calcification in chronic renal failure rats","volume":"346","author":"Phan","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"2019070203524493200_gfy127-B19","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/nep.12319","article-title":"Long-term sevelamer treatment lowers serum fibroblast growth factor 23 accompanied with increasing serum Klotho levels in chronic haemodialysis patients","volume":"19","author":"Lin","year":"2014","journal-title":"Nephrology"},{"key":"2019070203524493200_gfy127-B20","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2215\/CJN.05420709","article-title":"Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?","volume":"5","author":"Oliveira","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019070203524493200_gfy127-B21","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1093\/ndt\/gft203","article-title":"A comparison of calcium acetate\/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study","volume":"28","author":"Covic","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"2019070203524493200_gfy127-B22","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2014.10.014","article-title":"A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5","volume":"65","author":"Block","year":"2015","journal-title":"Am J Kidney Dis"},{"key":"2019070203524493200_gfy127-B23","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1053\/j.ajkd.2011.11.007","article-title":"Comparison of calcium acetate and sevelamer on vascular function and fibroblast growth factor 23 in CKD patients: a randomized clinical trial","volume":"59","author":"Yilmaz","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"2019070203524493200_gfy127-B24","doi-asserted-by":"crossref","first-page":"543","DOI":"10.2215\/CJN.05170513","article-title":"Ferric citrate hydrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD","volume":"9","author":"Yokoyama","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019070203524493200_gfy127-B25","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.2215\/CJN.03030317","article-title":"Randomized clinical trial of sevelamer carbonate on serum klotho and fibroblast growth factor 23 in CKD","volume":"12","author":"Liabeuf","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019070203524493200_gfy127-B26","article-title":"Effect of ferric citrate hydrate on FGF23 and PTH levels in patients with non-dialysis-dependent chronic kidney disease with normophosphatemia and iron deficiency","author":"Iguchi","year":"2017","journal-title":"Clin Exp Nephrol"},{"key":"2019070203524493200_gfy127-B27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000351811","article-title":"Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease","volume":"123","author":"Spatz","year":"2013","journal-title":"Nephron Clin Pract"},{"key":"2019070203524493200_gfy127-B28","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1159\/000440968","article-title":"Administration of ferric citrate hydrate decreases circulating FGF23 levels independently of serum phosphate levels in hemodialysis patients with iron deficiency","volume":"131","author":"Iguchi","year":"2015","journal-title":"Nephron"},{"key":"2019070203524493200_gfy127-B29","doi-asserted-by":"crossref","first-page":"F1088","DOI":"10.1152\/ajprenal.00474.2004","article-title":"Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism","volume":"289","author":"Shimada","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"2019070203524493200_gfy127-B30","doi-asserted-by":"crossref","first-page":"4469","DOI":"10.1210\/en.2013-1627","article-title":"Calcium regulates FGF-23 expression in bone","volume":"154","author":"David","year":"2013","journal-title":"Endocrinology"},{"key":"2019070203524493200_gfy127-B31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/978-1-4614-0887-1_8","article-title":"FGF23 in chronic kidney disease","volume":"728","author":"Wahl","year":"2012","journal-title":"Adv Exp Med Biol"},{"key":"2019070203524493200_gfy127-B32","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1161\/CIRCULATIONAHA.108.844506","article-title":"Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease","volume":"119","author":"Guti\u00e9rrez","year":"2009","journal-title":"Circulation"},{"key":"2019070203524493200_gfy127-B33","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s11255-016-1231-1","article-title":"FGF-23 levels are associated with vascular calcification, but not with atherosclerosis, in hemodialysis patients","volume":"48","author":"Turan","year":"2016","journal-title":"Int Urol Nephrol"},{"key":"2019070203524493200_gfy127-B34","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1172\/JCI83470","article-title":"FGF23 signaling impairs neutrophil recruitment and host defense during CKD","volume":"126","author":"Rossaint","year":"2016","journal-title":"J Clin Invest"},{"key":"2019070203524493200_gfy127-B35","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.kint.2016.05.019","article-title":"Fibroblast growth factor 23 directly targets hepatocytes to promote inflammation in chronic kidney disease","volume":"90","author":"Singh","year":"2016","journal-title":"Kidney Int"},{"key":"2019070203524493200_gfy127-B36","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2147\/PPA.S43486","article-title":"Patient education for phosphorus management in chronic kidney disease","volume":"7","author":"Kalantar-Zadeh","year":"2013","journal-title":"Patient Prefer Adherence"},{"key":"2019070203524493200_gfy127-B37","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1038\/ki.2011.490","article-title":"Calcium balance in normal individuals and in patients with chronic kidney disease on low- and high-calcium diets","volume":"81","author":"Spiegel","year":"2012","journal-title":"Kidney Int"},{"key":"2019070203524493200_gfy127-B38","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/01.mnh.0000447014.36475.58","article-title":"Can one evaluate bone disease in chronic kidney disease without a biopsy?","volume":"23","author":"Babayev","year":"2014","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2019070203524493200_gfy127-B39","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000447600","article-title":"Pharmacodynamic effects of sucroferric oxyhydroxide and sevelamer carbonate on VDRA bioactivity in dialysis patients","volume":"44","author":"Sprague","year":"2016","journal-title":"Am J Nephrol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/34\/7\/1163\/28889154\/gfy127.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T07:53:02Z","timestamp":1562053982000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/34\/7\/1163\/5017393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,29]]},"references-count":39,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,5,29]]},"published-print":{"date-parts":[[2019,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfy127","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,7]]},"published":{"date-parts":[[2018,5,29]]}}}